Eucrisa

The active ingredient in Eucrisa is crisaborole, which is a phosphodiesterase 4 inhibitor. The mechanism of action involves inhibiting PDE4, a protein implicated in skin inflammation and dermatitis. Eucrisa is believed to help treat eczema by reducing inflammation, itching, and redness by blocking PDE4.

Eucrisa is a nonsteroidal treatment option that works differently from topical corticosteroids. They work to reduce inflammation in the skin by preventing cells from producing inflammation-causing chemicals.

Follow all directions given to you by your doctor and read all documents provided, including the full Prescribing Information, FDA-Approved Product Labeling, Instructions for Use, and Medication Guide before using Eucrisa. However, the following is a synopsis of the general guidelines for the use of Eucrisa:

• Eucrisa is for topical use only and is not for oral, ophthalmic, or intravaginal use.
• Twice a day, apply a thin layer of the topical treatment to the affected area.
• After application, wash your hands, unless you are treating hand eczema.

The most common side effects of Eucrisa seen in clinical trials include:

• Itchy, red skin rash or hives.
• Application site pain, burning, or stinging.

Some individuals may experience serious adverse events while using Eucrisa. These may require immediate medical attention. If you experience any of the following, contact your healthcare provider or seek emergency medical help:

• Allergic reaction to the medication, such as red rash, severe swelling of the skin, lips, tongue, or face, shortness of breath, chest tightness.

These are not all of the possible side effects of Eucrisa. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Before starting Eucrisa, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including if you:

• Have an allergy to crisaborole or any of the inactive ingredients in the product.
• Are younger than 3 months old.

• Hypersensitivity reactions to the medication.

After a week of treatment, some participants in trials reported improvements in their skin. However, it took a few weeks for the majority of people to see clear or almost clear skin after taking Eucrisa. If you don't immediately notice an improvement in your skin, don't give up.

When Eucrisa is taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions. However, Eucrisa ointment used on the skin is not likely to be affected by other drugs you use.

On any eczema-affected regions of your skin, apply a thin coating of the ointment twice a day. Your doctor may reduce your dose to once daily after your skin becomes better.

Store at room temperature and keep tightly closed.

Pfizer Inc. Dermatology is the pharmaceutical company that manufactures Eucrisa.

There is no generic version available of Eucrisa.

You should only stop taking Eucrisa (crisaborole ointment) if your doctor advises you to. You should stop using the product right away and get medical help if you have a hypersensitivity reaction.

It is not known whether Eucrisa can cause harm to your unborn baby. Discuss with your healthcare provider about the risks and benefits of using Eucrisa during pregnancy.

It is not known if Eucrisa is found in breast milk. Talk to your doctor if you are already breastfeeding or if you have any plans to breastfeed. They will know or recommend what is best for you.